Japan Approves First Stem Cell Therapy for Parkinson’s Disease

In a landmark achievement for regenerative medicine, Japan has granted conditional approval for Amchepry, a novel stem cell therapy for Parkinson’s disease. The treatment, developed by Sumitomo Pharma, utilizes induced pluripotent stem (iPS) cells to potentially slow the progression of the debilitating neurological disorder. This approval marks the first time a therapy derived from iPS cells has been authorized for widespread use, offering new hope for patients who don’t respond adequately to existing medications.

How Amchepry Works: Harnessing the Power of iPS Cells

The breakthrough stems from the pioneering research of Japanese scientist Shinya Yamanaka, who was awarded the Nobel Prize in 2012 for his discovery of iPS cells. These cells possess the remarkable ability to differentiate into any cell type in the body. In the case of Amchepry, healthy donor iPS cells are reprogrammed to become precursors of dopamine-producing neurons – the cells lost in Parkinson’s disease . These precursor cells are then transplanted into the brains of patients, aiming to replenish the dopamine supply and alleviate motor symptoms like tremors and rigidity.

Clinical Trial Results: Safety and Early Signs of Efficacy

The approval follows a clinical trial involving seven adults with Parkinson’s disease, aged 50 to 69 . Participants received either five or ten million cells implanted on both sides of the brain. After a two-year follow-up period, researchers observed improvements in motor symptoms in four patients. Importantly, the trial demonstrated the safety of the procedure, with no reports of cell migration to other parts of the body or any deaths .

Conditional Approval and Future Availability

The Japanese Ministry of Health has granted a conditional and time-limited marketing authorization for Amchepry, valid for seven years . This means the treatment will be available to patients in the coming months, potentially as early as this summer, pending government decisions regarding pricing and health insurance coverage . The seven-year period will allow for continued monitoring of the therapy’s long-term safety and effectiveness.

A Second iPS Cell Therapy Approved: ReHeart for Heart Failure

Alongside Amchepry, Japan also approved ReHeart, a stem cell therapy developed by Qualipse for severe heart failure due to ischemic cardiomyopathy . ReHeart utilizes a sheet of heart muscle cells (cardiomyocytes) derived from iPS cells to repair damaged heart tissue. This dual approval signifies a major milestone in the field of regenerative medicine, demonstrating the potential of iPS cell-based therapies to address a range of debilitating conditions.

Looking Ahead: The Future of iPS Cell Therapies

Shinya Yamanaka, director emeritus of the iPS Cell Research Institute at Kyoto University, emphasized the importance of continued scientific rigor in developing and implementing these therapies. “To establish it as a medical treatment, it is essential to move through the process of confirming its safety and efficacy in many more cases,” he stated . The approvals in Japan are expected to accelerate research and development in iPS cell therapies globally, potentially leading to treatments for a wider array of diseases, including diabetes and other neurodegenerative disorders.